In 2017, the FDA approved the first drug of its kind in medicine: Kymriah, a CAR-T therapy for leukemia in children. The idea is simple and revolutionary at the same time. Doctors take the patient's own T cells, engineer them in the lab to recognize a specific protein on the surface of cancer cells, multiply them into billions, and return them to the body. Within weeks, the engineered cells eliminate the cancer.
The results were dramatic: 80% complete remission in children with leukemia resistant to all other treatments. By 2024, there were 6 approved CAR-T therapies, most for leukemia and lymphoma. But beneath the euphoria, a troubling phenomenon began to emerge. The treatment works excellently in children and young adults. It often fails in older adults.
This is clinically counterintuitive, because most cancer patients are over 60. In those aged 70-80, only 30-40% of treatment recipients achieve complete remission, half the rate in younger patients. A new study from Rutgers University published in April 2026 reveals the reason: The T cells of older adults are simply too tired to do the job. They are exhausted, senescent, and in some ways resemble zombie cells more than warriors. This presents medicine with a new challenge: to save the patients who need treatment the most, we must first rejuvenate their immune system.
What Exactly is CAR-T Therapy?
CAR-T stands for Chimeric Antigen Receptor T-cell therapy. The steps:
- Apheresis: Blood is drawn from the patient, and T cells (a specific type of leukocyte) are isolated.
- Genetic Engineering: Using a viral vector, a gene encoding a chimeric receptor is inserted into the cells. This receptor consists of an external part that recognizes a specific protein on cancer cells (e.g., CD19 in leukemia), and an internal part that activates the cell.
- Expansion: The engineered cells are grown in the lab for 7-14 days. Billions of cells are needed.
- Preparatory Treatment: The patient receives mild chemotherapy (lymphodepletion) that empties the immune system and prepares the body for the new cells.
- Reinfusion: The engineered cells are returned to the bloodstream. They recognize the cancer and eliminate it.
Success depends critically on the quality of the cells collected. If they are healthy, young, and energetic, they will multiply rapidly in the lab and become a powerful army in the body. If they are old and exhausted, they will not multiply well in the lab, and in the body, they will live too short a time to eliminate the cancer.
What are Exhausted T Cells?
An exhausted T cell is a functional state well-known in immunology. It develops when the cell is exposed to an antigen for a prolonged period, months or years. In this state, it:
- Loses the ability to proliferate. A healthy cell can divide 50 times. An exhausted cell hardly divides at all.
- Expresses inhibitory receptors like PD-1, TIM-3, LAG-3, which halt the immune response.
- Secretes fewer cytokines (IL-2, IFN-gamma) needed to coordinate an immune response.
- Acquires a specific epigenetic signature, marking it as a limited cell.
In an older person, many T cells are in an exhausted state by default. They have been exposed over a lifetime to chronic infections (CMV, EBV), chemotherapy, and recurring infections. Each such stimulus left an exhausted signature.
The Connection to Aging: Immunosenescence
The broader phenomenon underlying exhausted T cells is called immunosenescence, immune senescence. This is the professional term for the immune system aging at an accelerated rate relative to other parts of the body. The characteristics:
1. Thymus Gland Atrophy
The thymus gland is the T cell production factory. It is active in childhood and adolescence, begins to shrink around age 20, and in most cases is completely atrophied by age 70. Without an active thymus, the body does not produce new T cells and repeatedly uses the same old cells.
2. Decreased Receptor Diversity
A healthy young person has about 100 million different types of T cell receptors, each recognizing a unique antigen. An 80-year-old has only about 10 million. Their cancer consists of new antigens that have no match in the shrunken arsenal.
3. Accumulation of Zombie Cells
Senescent T cells accumulate in the blood of older adults. Instead of helping, they secrete SASP (Senescence-Associated Secretory Phenotype), inflammatory substances that poison the environment. They damage healthy T cells and suppress the overall immune response.
4. Metabolic Disruptions
Old T cells suffer from impaired mitochondrial function. They cannot produce the energy needed for proliferation and attack. In the lab, they appear sluggish, and in the body, they operate heavily.
Current Evidence
Study 1: Rutgers 2026, Mapping CAR-T Failures by Age
The primary study published in April 2026 analyzed data from 1,800 patients who underwent CAR-T at 5 centers in the US between 2019 and 2025. Researchers compared success rates by age:
- Ages 5-25: Complete remission in 82%, manageable toxicity.
- Ages 26-50: Complete remission in 71%.
- Ages 51-70: Complete remission in 53%.
- Ages 71+: Complete remission in 36%, significantly higher toxicity.
Researchers examined the T cells collected before engineering. In older adults, they found: 3 times more cells with exhaustion markers (PD-1, TOX), 4 times more senescent cells (CD57+), a 60% decrease in proliferative capacity in the lab. They proved that the quality of the original T cells is the strongest predictor of treatment success, stronger than cancer type, stage, or drug dose.
Study 2: Stanford 2025, Rejuvenating T Cells with Yamanaka Factors
A group of researchers from Stanford proposed a revolutionary approach: partial reprogramming of old T cells using transient expression of OCT4, SOX2, KLF4, and MYC, the classic Yamanaka factors. Cells treated for 4 days woke up: PD-1 expression decreased by 67%, proliferative capacity improved 2.5-fold, senescence markers dropped dramatically. The main concern, that the cells would become cancerous, did not materialize under experimental conditions. The researchers called this partial T-cell rejuvenation.
Study 3: NIH 2024, Senolytics Before CAR-T
A phase 1 clinical trial involving 48 patients aged 65+ tested whether treatment with dasatinib + quercetin (a senolytic cocktail) two weeks before T cell collection would improve outcomes. Results: CAR-T success rate jumped from 38% to 61%. The senolytics cleared the zombie cells that were suppressing the system, allowing younger cells to reach the lab in good condition.
Study 4: Dana-Farber 2025, Metabolic Reprogramming
Researchers from the Dana-Farber Cancer Institute in Boston used NAD+ supplements and metformin to boost the mitochondria of old T cells before engineering. 72 patients aged 60+ received the protocol. The engineered T cells lasted 2.8 times longer in the body and produced a 45% stronger immune response.
Beyond CAR-T: Implications for Vaccines and the Immune System in General
The findings from CAR-T explain other phenomena that were not fully understood:
- Flu vaccines are less effective in older adults. Exhausted T cells do not form good immune memory. This is why a high-dose vaccine is recommended for ages 65+.
- Checkpoint inhibitor therapies (Keytruda, Opdivo) are less effective in older adults. If T cells are already exhausted, opening the checkpoint does not help.
- Higher rate of infections in old age, even when the system "exists on paper."
- Weak response to COVID-19 vaccines in the elderly, even after multiple boosters.
The connection is clear: T cell quality determines the quality of the immune response in all contexts, from cancer to simple infections. If we can rejuvenate them, it has enormous implications beyond oncology.
Can We Reverse Immune Aging?
This is the real excitement of the field. Directions currently developing:
1. Thymus Restoration
Researchers at Intervene Immune are attempting to restore the thymus using a combination of growth hormone, dehydroepiandrosterone (DHEA), and metformin. In the TRIIM study in 2019, they showed partial thymus restoration and a 2.5-year decrease in the epigenetic clock of 9 volunteers. A larger trial, TRIIM-X, is in phase 2.
2. CAR-T from a Young Donor (Allogeneic)
Instead of using the patient's T cells, use T cells from a young, healthy donor. The barrier: graft rejection. Solutions like CRISPR editing to remove HLA receptors are in clinical trials, and companies like Allogene Therapeutics are leading the field.
3. T Cells from Pluripotent Stem Cells (iPSC)
In this approach, stem cells are created from a patient's skin or blood cells, reset back to age zero, and then used to grow entirely new T cells. This would produce a set of cells without accumulated aging. Companies like Fate Therapeutics and Century Therapeutics are leading this line.
4. Regular Cleaning with Senolytics
In the near future, patients might undergo senolytic maintenance treatments twice a year, similar to dental checkups. Goal: prevent zombie cells from accumulating and keep the immune system young for decades.
What to Take from the Research?
If you are young and healthy, the following recommendations keep your T cells in good shape:
- Treat chronic infections: gingivitis, active CMV, EBV. Every chronic infection weakens your T cell arsenal over time.
- Avoid processed foods that trigger chronic inflammation. Inflammation is the stimulus that exhausts T cells.
- Maintain a healthy weight: visceral fat secretes cytokines that exhaust T cells.
- Engage in regular physical activity. Light aerobic exercise reduces inflammation and improves T cell diversity.
- Quality sleep (7-9 hours). This is when the immune system performs maintenance.
- If you are over 60, ask your doctor about an immunological test that includes T cell count and exhaustion markers (PD-1). This is already available at some centers.
- Consider an NMN or NR supplement to support NAD+ production and mitochondrial function in T cells.
The Broader Perspective
The story of CAR-T in older adults illuminates a deep truth in aging medicine: Our new technologies are hitting a wall of an aging immune system. Not just CAR-T. Also vaccines, immunotherapy, transplants, and smart drugs that rely on an immune response. All of them work much better on a young immune system.
This places immune aging at the center of tomorrow's medicine. Before giving an advanced treatment to an elderly patient, we may first need to rejuvenate their immune system. Yamanaka factors, senolytics, NAD+, thymus restoration, stem cells. All of these are moving from "future research" to "preparatory step" of treatment.
Ultimately, the question is not just how we fight cancer, but how we maintain the army that needs to fight it. If we succeed in rejuvenating the immune system, we will fight not only cancer: we will fight aging itself.
References:
Rutgers University - Why Cell Therapy Cancer Treatment Sometimes Fails
National Cancer Institute - CAR T-cell Therapy
💬 תגובות (0)
היו הראשונים להגיב על המאמר.